Peripheral T-Cell Lymphoma: Clinical Trials

74 trials for Peripheral T-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

45 completed, 9 terminated, 9 unknown, 7 recruiting. 74 Phase 2, 21 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 274Completed 45, Terminated 9, Unknown 9, Recruiting 7, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1
Phase 121Completed 9, Recruiting 4, Terminated 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1

Follow Peripheral T-Cell Lymphoma: new trials by email Literature Review of Peripheral T-Cell Lymphoma trials Research Report on Peripheral T-Cell Lymphoma

Trials (filtered) newest first · largest first

All 74 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy of CAPCT in Patients With PTCL
Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma
Phase 2Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University582026-08-012026-08-05
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Phase 1 / Phase 2RecruitingBeijing Biotech962026-03-022026-04-13
Amping up With PemJAK
Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma
Phase 2RecruitingSeda S. Tolu532025-12-032025-12-16
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma
Phase 1 / Phase 2RecruitingEvopoint Biosciences Inc.1762025-08-152026-07-29
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
chidamide and golidocitinib - Peripheral T-cell Lymphoma
Phase 1 / Phase 2Not yet recruitingPeking University Cancer Hospital & Institute452024-12-302025-01-03
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Golidocitinib plus CHOP - Peripheral T-cell Lymphoma
Phase 1 / Phase 2RecruitingPeking Union Medical College Hospital682024-09-012024-12-18
Linperlisib Combined With Chidamide in Patients With PTCL
Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone - Peripheral T-cell Lymphoma
Phase 1 / Phase 2RecruitingYanyan Liu1342024-05-252025-12-05
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma
Phase 1 / Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.1002023-12-222024-05-14
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Linperlisib in combination with CHOP - Peripheral T-cell Lymphoma
Phase 1 / Phase 2Active not recruitingSun Yat-sen University442023-08-152026-09-16
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin - Treatment, Peripheral T-cell Lymphoma
Phase 1 / Phase 2UnknownPeking Union Medical College Hospital602022-05-012022-07-01
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
AZD4205 - Peripheral T-cell Lymphoma
Phase 2CompletedDizal Pharmaceuticals482022-03-172025-07-04
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Sintilimab, Chidamide, Azacidine - Peripheral T-cell Lymphoma
Phase 2UnknownPeking University302021-04-152021-03-09
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Lenalidomide, Cyclophosphamide, Doxorubicin - Peripheral T-Cell Lymphoma, Lenalidomide
Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2892021-04-012022-11-07
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)
TQ-B3525 - Peripheral T-cell Lymphoma
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.782020-12-012020-11-04
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
PD-1 antibody+ HDAC inhibitor - Peripheral T-cell Lymphoma
Phase 2RecruitingFudan University512020-11-132026-04-02
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
brentuximab vedotin, cyclophosphamide, doxorubicin - Peripheral T-cell Lymphoma
Phase 2CompletedSeagen, a wholly owned subsidiary of Pfizer822020-11-122026-08-13
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia
Phase 2CompletedOhio State University Comprehensive Cancer Center62020-09-152025-02-28
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab - Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
Phase 1 / Phase 2TerminatedAntengene Corporation562020-08-182026-01-05
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
CHOP, CHOP+X - Peripheral T-cell Lymphoma
Phase 2UnknownRuijin Hospital962020-07-292023-06-13
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
Azacitidine, Chidamide - Peripheral T-cell Lymphoma
Phase 2UnknownRuijin Hospital282020-06-202022-04-20

Showing 20 of 74. Sign in to see all of them.

Narrower conditions

Lymphoma, T-Cell, Peripheral (74)  ·  Lymphoma, T-Cell, Cutaneous (26)  ·  Immunoblastic Lymphadenopathy (24)  ·  Lymphoma, Large-Cell, Anaplastic (24)  ·  Lymphoma, Non-Hodgkin (24)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (23)  ·  Lymphoma, Large B-Cell, Diffuse (23)  ·  Lymphoma, Extranodal NK-T-Cell (22)  ·  Lymphoma, Follicular (22)  ·  Lymphoma, Mantle-Cell (22)  ·  Mycosis Fungoides (22)  ·  Sezary Syndrome (22)  ·  Lymphoma, B-Cell, Marginal Zone (21)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (21)  ·  Hodgkin Disease (20)

Broader conditions

Hemic and Lymphatic Diseases (74)  ·  Immune System Diseases (74)  ·  Immunoproliferative Disorders (74)  ·  Lymphatic Diseases (74)  ·  Lymphoproliferative Disorders (74)  ·  Neoplasms by Histologic Type (74)  ·  Neoplasms (72)  ·  Lymphoma, T-Cell (68)  ·  Lymphoma (66)  ·  Lymphoma, Non-Hodgkin (50)  ·  Hematologic Diseases (29)  ·  Disease Attributes (27)  ·  Leukemia (27)  ·  Leukemia, Lymphoid (27)  ·  Pathologic Processes (27)

Interventions

Cyclophosphamide (15)  ·  Prednisone (10)  ·  Whole-Body Irradiation (10)  ·  Mycophenolic Acid (9)  ·  fludarabine phosphate (9)  ·  Peripheral Blood Stem Cell Transplantation (8)  ·  Cyclosporine (7)  ·  Doxorubicin (7)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (7)  ·  Vincristine (7)  ·  Etoposide (6)  ·  Alemtuzumab (5)  ·  Gemcitabine (5)  ·  Lenalidomide (5)  ·  10-propargyl-10-deazaaminopterin (4)

Sponsors

Fred Hutchinson Cancer Center (9)  ·  Kyowa Kirin Co., Ltd. (3)  ·  Acrotech Biopharma Inc. (2)  ·  Mayo Clinic (2)  ·  National Cancer Institute (NCI) (2)  ·  Northwestern University (2)  ·  Peking Union Medical College Hospital (2)  ·  Ruijin Hospital (2)  ·  Sun Yat-sen University (2)  ·  University of Nebraska (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Aileron Therapeutics, Inc. (1)  ·  Akeso (1)  ·  Antengene Corporation (1)  ·  Asana BioSciences (1)

Countries

United States (43)  ·  China (18)  ·  Italy (12)  ·  France (7)  ·  United Kingdom (6)  ·  Germany (5)  ·  Japan (4)  ·  Spain (4)  ·  Belgium (3)  ·  Canada (3)  ·  Denmark (3)  ·  Thailand (3)  ·  Israel (2)  ·  Netherlands (2)  ·  Poland (2)

Top investigators

Brenda Sandmaier (3)  ·  Ajay Gopal (2)  ·  David Maloney (2)  ·  Adam Lerner, MD (1)  ·  Adam Petrich, MD (1)  ·  Alain Delmer, MD (1)  ·  Amanda Cashen, MD (1)  ·  Andreas Neubauer, MD (1)  ·  Andreas Viardot, MD (1)  ·  Andrei Shustov, MD (1)  ·  Beata Holkova, MD (1)  ·  Bernard Poiesz, MD (1)  ·  Bertrand Coiffier, MD (1)  ·  Charles Farber, MD (1)

Results publications

PMID 32499241, PMID 19900571, PMID 21504290, PMID 22271479, PMID 24456586, PMID 25279222, PMID 25404094, PMID 25605368, PMID 25605745, PMID 26213141, PMID 26764356, PMID 26921086, PMID 26965915, PMID 27071522, PMID 27418646, PMID 28420721, PMID 28771889, PMID 30952672, PMID 31917843, PMID 33236943, PMID 34230007, PMID 34670169, PMID 36399518, PMID 36661315, PMID 37319432, PMID 37327113, PMID 39175480, PMID 42018969, PMID 42438166

NIH funding

P30CA015704 (7), P01CA018029 (3), P01CA078902 (2), 2008 (1), 2019 (1), N01CM00039 (1), N01CM62202 (1), P30CA016672 (1), P30CA036727 (1), P30CA060553 (1), P30CA072720 (1), U10CA021115 (1)